Claims

1. A composition comprising a combination of at least two active ingredients, wherein one of the active ingredients is an FGF-18 compound, wherein the FGF-18 compound is selected from the group consisting of:

a) a polypeptide comprising or consisting of the human FGF-18 mature form comprising residues 28-207 of SEQ ID NO:1, or

b) a polypeptide comprising or consisting of SEQ ID NO:2,

and wherein the at least one other active ingredient is selected from the group consisting of Botulinum Neurotoxin Type A, anti-IL-6 antibody or nanobody, anti-IL-6 receptor antibody and anti-NGF antibody.

2. The composition according to claim 1 for use in the treatment of a cartilage disorder.

3. The composition for use according to claim 1, wherein the composition is to be administered intra-articularly.

4. An FGF-18 compound, wherein the FGF-18 compound is selected from the group consisting of:

a) a polypeptide comprising or consisting of the human FGF-18 mature form comprising residues 28-207 of SEQ ID NO:1, or

b) a polypeptide comprising or consisting of SEQ ID NO:2,

for use in the treatment of a cartilage disorder in combination with at least one further active ingredient, wherein said at least one further active ingredient is selected from the group consisting Botulinum Neurotoxin Type A, anti-IL-6 antibody or nanobody, anti-IL-6 receptor antibody and anti-NGF antibody.

5. The composition for use according to claim 2 or the FGF-18 compound for use according to claim 4, wherein the cartilage disorder is osteoarthritis.

6. The composition for use according to claim 2 or the FGF-18 compound for use according to claim 4, wherein the cartilage disorder is cartilage injury.